Figure 1. Efficacy of DC-mv for tumor rejection in vivo. Mice were vaccinated twice a week intervals with either saline (control), DC-mv from immature DCs (DC-mvblank), DC-mv carrying antigens from B16 cells (DC-mvB16) or DC-mv carrying antigens from B16 and LLC cells (DC-mvB16/LLC). Mice were then injected with B16 (A) or LLC (B) tumor cells 7 d after the last vaccination. DC-mvB16/LLC vaccine showed highly inhibition effect on tumor growth for both B16 and LLC cell-challenged mice. Adapted from Tian et al.15